CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Celgene Corporation v. Teva Pharmaceuticals USA, Inc.

1:15-cv-00589

Overview

Case Number 1:15-cv-00589
Filing Date 2015-07-10
Status Terminated
Termination Date 2016-08-08
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

4 Attorneys Listed

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

David M. Fry

JPMorgan Chase & Co.

Tel: +1 (302) 455-3374

JPMorgan Chase & Co., 4041 Ogletown Stanton Road

Julia M. Johnson

Email: jmjohnson@winston.com

Bryce A. Cooper

Email: bcooper@winston.com

Plaintiff

Astellas Pharma, Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Celgene Corporation NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 13 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (13): FR πŸ‡―πŸ‡΅ Japan πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7608280
Method of producing FR901228
Filed: 2008-03-17
Issued: 2009-10-27
Active (1.3 yrs remaining)
Expires: 2028-03-17
US7611724
Method of producing FR901228
Filed: 2009-03-03
Issued: 2009-11-03
Active (2.3 yrs remaining)
Expires: 2029-03-03

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

3

Dispositive

0

Granted

0

Denied

0

Pending / Review

3

Motions by Category

Claim Construction / Markman Filing 3

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
APPENDIX re 26 Claim Construction Chart, by Astellas Pharma, Inc., Celgene Corporation. (Attachments: # 1 Part 2)(Noreika, Maryellen) Modified on 5/6/2016 (nms)...
Entry #37 • 2016-05-05 Document →
Claim Construction / Markman Filing Pending / Under Review
Joint CLAIM Construction Chart, by Astellas Pharma, Inc., Celgene Corporation. (Noreika, Maryellen) Modified on 2/24/2016 (nms). (Entered: 02/23/2016)
Entry #26 • 2016-02-23 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 8/15/2016. Amended Pleadings due by 8/15/201...
Entry #15 • 2015-09-29 Document →

Docket Entries

(61 total)
Pleading / Complaint

COMPLAINT filed against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1752752.) - filed by Celgene Corporation, Astellas Pharma, Inc.. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(nmb) (Entered: 07/10/2015)

Entry #1 • 2015-07-10
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmb) (Entered: 07/10/2015)

Entry #2 • 2015-07-10
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: On or about 5/28/15. Date of Expiration of Patent: 8/22/2021.Thirty Month Stay Deadline: 11/28/2017. (nmb) (Entered: 07/10/2015)

Entry #3 • 2015-07-10
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,608,280 B2; 7,611,724 B2;. (nmb) (Entered: 07/10/2015)

Entry #4 • 2015-07-10
1

Summons Issued

Entry #5 • 2015-07-10
1
No Actions

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc